ly3832479
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 19, 2020 (NCT04441931)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04611789 | Phase 1 | Nov 2, 2020 | Eli Lilly, Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04634409 | Phase 2 | Oct 29, 2020 | AbCellera Biologics Inc., Eli Lilly, Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04497987 | Phase 3 | Aug 2, 2020 | AbCellera Biologics Inc., Eli Lilly, National Institute of Allergy and Infectious Diseases (NIAID), Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04441931 | Phase 1 | Jun 19, 2020 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 3 | 2020 |
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 3 | 0 | 3 | 2020 |
| AbCellera Biologics Inc. | For profit | 2 | 0 | 2 | 2020 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1